302 related articles for article (PubMed ID: 29357824)
1. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H
BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824
[TBL] [Abstract][Full Text] [Related]
2. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
3. Endometrial stromal sarcoma: objective response to letrozole.
Maluf FC; Sabbatini P; Schwartz L; Xia J; Aghajanian C
Gynecol Oncol; 2001 Aug; 82(2):384-8. PubMed ID: 11531300
[TBL] [Abstract][Full Text] [Related]
4. Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Leiser AL; Hamid AM; Blanchard R
Gynecol Oncol; 2004 Aug; 94(2):567-71. PubMed ID: 15297205
[TBL] [Abstract][Full Text] [Related]
5. YWHAE-FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin-embedded tumor.
Isphording A; Ali RH; Irving J; Goytain A; Nelnyk N; Hoang LN; Gilks CB; Huntsman DG; Nielsen TO; Nucci MR; Lee CH
Hum Pathol; 2013 May; 44(5):837-43. PubMed ID: 23159154
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes.
Henriksen JN; Bøttger P; Hermansen CK; Ladefoged SA; Nissen PH; Hamilton-Dutoit S; Fink TL; Donskov F
Clin Genitourin Cancer; 2020 Feb; 18(1):62-68.e2. PubMed ID: 31640912
[TBL] [Abstract][Full Text] [Related]
7. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole.
Leunen M; Breugelmans M; De Sutter P; Bourgain C; Amy JJ
Gynecol Oncol; 2004 Dec; 95(3):769-71. PubMed ID: 15582003
[TBL] [Abstract][Full Text] [Related]
8. Long-term multidisciplinary treatment including proton therapy for a recurrent low-grade endometrial stromal sarcoma and pathologically prominent epithelial differentiation: an autopsy case report.
Maeda O; Nagasaka T; Ito M; Mitsuishi T; Murakami F; Uematsu T; Hattori Y; Iwata H; Ogino H
BMC Womens Health; 2020 Jul; 20(1):154. PubMed ID: 32711524
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib efficacy and toxicity in a metastatic sarcoma cohort: Are Indian patients different?
Sharma A; Vanidassane I; Aggarwal A; Mridha AR; Pandey R; Dhamija E; Barwad A; Rastogi S
Indian J Cancer; 2019; 56(3):207-210. PubMed ID: 31389382
[TBL] [Abstract][Full Text] [Related]
10. Promising management of pazopanib-induced liver toxicity.
Vlenterie M; van Erp NP; van der Graaf WT
Acta Oncol; 2015 Jul; 54(7):1064-6. PubMed ID: 25734660
[No Abstract] [Full Text] [Related]
11. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H
J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550
[TBL] [Abstract][Full Text] [Related]
12. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M
Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537
[TBL] [Abstract][Full Text] [Related]
13. Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels.
Groenland SL; Katz D; Huitema ADR; Steeghs N
BMC Cancer; 2018 Dec; 18(1):1200. PubMed ID: 30509247
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib and pancreatic toxicity: a case report.
Russano M; Vincenzi B; Venditti O; D'Onofrio L; Ratta R; Guida FM; Tonini G; Santini D
BMC Res Notes; 2015 May; 8():196. PubMed ID: 25967382
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report.
Maeda O; Moritani S; Ichihara S; Inoue T; Ishihara Y; Yamamoto S; Ito M; Matsumura Y; Sugiyama K; Horio M; Kondo I
J Med Case Rep; 2015 Oct; 9():233. PubMed ID: 26481040
[TBL] [Abstract][Full Text] [Related]
16. Aggressive behavior and poor prognosis of endometrial stromal sarcomas with YWHAE-FAM22 rearrangement indicate the clinical importance to recognize this subset.
Kruse AJ; Croce S; Kruitwagen RF; Riedl RG; Slangen BF; Van Gorp T; Van de Vijver KK
Int J Gynecol Cancer; 2014 Nov; 24(9):1616-22. PubMed ID: 25244606
[TBL] [Abstract][Full Text] [Related]
17. Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.
Alkasi O; Meinhold-Heerlein I; Zaki R; Fasching P; Maass N; Jonat W; Beckmann MW
Arch Gynecol Obstet; 2009 Jan; 279(1):57-60. PubMed ID: 18379806
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma.
Lee CH; Ou WB; Mariño-Enriquez A; Zhu M; Mayeda M; Wang Y; Guo X; Brunner AL; Amant F; French CA; West RB; McAlpine JN; Gilks CB; Yaffe MB; Prentice LM; McPherson A; Jones SJ; Marra MA; Shah SP; van de Rijn M; Huntsman DG; Dal Cin P; Debiec-Rychter M; Nucci MR; Fletcher JA
Proc Natl Acad Sci U S A; 2012 Jan; 109(3):929-34. PubMed ID: 22223660
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study.
Sunar V; Korkmaz V; Akin S; Can Guven D; Arik Z; Ates O; Yilmaz M; Mutlu Meydanli M; Oksuzoglu B
J BUON; 2019; 24(6):2327-2332. PubMed ID: 31983102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
